Fortress Biotech, Inc. (FBIO) - Dilution Analysis

10-Q filing | 31.5M shares outstanding

10-K filing | 31.4M shares outstanding

8-K filing: Fortress Biotech, Inc. issued warrants to lenders to purchase up to 600,000 shares of common stock at a price of $2.62 per share in connection with an amendment to their credit agreement.

10-Q filing | 29.8M shares outstanding

10-Q filing | 29.6M shares outstanding

POS AM filing: This prospectus relates to the offer, sale and issuance by Fortress Biotech, Inc. of up to 5,885,000 shares of our common stock, par value $0.001 per share, at a purchase price of $1.65 per share upon exercise of the outstanding warrants issued November 10, 2023 and the offer, sale and issuance by the Company of up to 3,303,305 shares of our Common Stock, at a purchase price of $3.21 per share upon exercise of the outstanding warrants issued December 29, 2023 and the resale by certain selling stockholders of up to 116,637 shares of Common Stock issuable upon the exercise of outstanding warrants, as amended and the resale by certain selling stockholders who were previously holders of shares of 8% Cumulative Redeemable Perpetual Class B Preferred Stock of Urica Therapeutics, Inc. of an aggregate of 1,987,250 shares of Common Stock.

POS AM filing: This prospectus relates to the offer, sale and issuance by Fortress Biotech, Inc. of up to 5,885,000 shares of our common stock at a purchase price of $1.65 per share upon exercise of the outstanding warrants issued November 10, 2023, the offer, sale and issuance by the Company of up to 3,303,305 shares of our Common Stock at a purchase price of $3.21 per share upon exercise of the outstanding warrants issued December 29, 2023, the resale by certain selling stockholders of up to 116,637 shares of Common Stock issuable upon the exercise of outstanding warrants, as amended, and the resale by certain selling stockholders who were previously holders of shares of 8% Cumulative Redeemable Perpetual Class B Preferred Stock of Urica Therapeutics, Inc. of an aggregate of 1,987,250 shares of Common Stock.

POS AM filing: This is a prospectus for the offer, sale, and issuance of common stock upon exercise of outstanding warrants, and for the resale of common stock by selling stockholders.

POS AM filing: This is a POS AM filing for Fortress Biotech, Inc. registering the offer, sale, and issuance of common stock upon exercise of warrants, as well as the resale of common stock by selling stockholders.

10-K filing | 27.9M shares outstanding

10-Q filing | 27.6M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholders of (i) up to 506,390 shares of our common stock, issuable upon exercise of the warrants granted to Oaktree Fund Administration, LLC and certain of its affiliates, (ii) up to 14,450 shares of Common Stock the resale of which is now registrable as a result of the anti-dilution mechanism of the warrants granted to certain of the Selling Stockholders (iii) up to 202,834 shares of Common Stock issuable upon exercise of the warrants granted to certain affiliates of Harley Capital, LLC (iv) up to 4,702,753 shares of Common Stock issuable upon exercise of the warrants sold to certain Selling Stockholders and (v) 763,359 shares of Common Stock issued to Lindsay A. Rosenwald, M.D., our Chairman, President and Chief Executive Officer.

8-K filing: Fortress Biotech, Inc. completed a registered offering of 3,939,394 shares of common stock at $1.65 per share, raising approximately $6.5 million, and concurrently closed two private placements, one to accredited investors for warrants to purchase 3,939,394 shares and another to Lindsay A. Rosenwald, M.D., for 763,359 shares of common stock at $1.84 per share and warrants to purchase 763,359 shares, raising approximately $1.5 million. ($8.0M proceeds)

10-Q filing | 22.6M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 2,353,393 shares of common stock by selling stockholders, including shares issuable as dividends and shares issuable upon exchange of preferred stock.

S-3/A filing: S-3/A filing registering an indeterminate number of common stock, preferred stock, debt securities, warrants and/or units, with an aggregate initial offering price not to exceed $50,000,000.

S-3 filing: The filing relates to a shelf registration for the potential offering of common stock, preferred stock, warrants, and debt securities, either separately or in units, up to an aggregate amount of $50,000,000.

10-Q filing | 19.4M shares outstanding

10-K filing | 15.1M shares outstanding

8-K filing: Fortress Biotech, Inc. closed an offering of 3,303,305 units, each consisting of one share of common stock and one warrant, at a price of $3.33 per unit, resulting in gross proceeds of approximately $11.0 million before deductions. ($11.0M proceeds)

8-K filing: Fortress Biotech, Inc. completed a public offering of 5,885,000 units, each consisting of one share of common stock and one warrant, at a price of $1.70 per unit, resulting in gross proceeds of approximately $10.0 million before deducting fees and expenses. ($10.0M proceeds)

10-Q filing | 8.9M shares outstanding

10-Q filing | 131.7M shares outstanding

8-K filing: Fortress Biotech, Inc. lowered the exercise price of existing warrants to $0.5424 per share and issued amended and restated warrants in exchange for the Agent and Lenders' agreement to permit certain actions.

10-Q filing | 130.4M shares outstanding

S-3/A filing: This prospectus relates to the resale by the selling stockholders of up to 647,000 shares of our Common Stock, par value $0.001 per share, issuable in connection with the Dividend Payment and Exchange Agreement dated as of December 27, 2022.

10-K filing | 110.5M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders of up to 647,000 shares of our Common Stock, issuable in connection with the Dividend Payment and Exchange Agreement dated as of December 27, 2022 executed by Fortress Biotech, Inc. for the benefit of the holders of Urica Therapeutics, Inc. 8% Cumulative Redeemable Perpetual Class B Preferred Stock, and pursuant to the terms of the Urica Preferred Stock.

8-K filing: Fortress Biotech, Inc. entered into a Securities Purchase Agreement to issue and sell 16,642,894 shares of common stock at a price of $0.835 per share in a registered direct offering and also entered into a Letter Agreement for a private placement offering of rights to acquire warrants to purchase approximately 3.474% of the common stock of certain of the Company's subsidiaries. ($13.9M proceeds)

10-Q filing | 108.3M shares outstanding

10-Q filing | 107.7M shares outstanding

10-Q filing | 106.3M shares outstanding

10-K filing | 101.4M shares outstanding

POS AM filing: This prospectus relates to the resale by the selling stockholders named herein, or their pledgees, donees, transferees or other successors in interest, from time to time, of up to 600,000 shares of our common stock.

10-Q filing | 98.7M shares outstanding

POS AM filing: This POS AM filing registers 600,000 shares of common stock for resale by selling stockholders, issuable in connection with a Dividend Payment and Exchange Agreement. Fortress Biotech, Inc. will not receive any proceeds from the sale.

POS AM filing: This POS AM filing relates to the resale of up to 600,000 shares of common stock by selling stockholders, issuable in connection with a Dividend Payment and Exchange Agreement.

POS AM filing: The Registrant is registering for resale of up to 600,000 shares of common stock.

10-Q filing | 97.5M shares outstanding

S-3 filing: The company is filing an S-3 to register an indeterminate number of shares of common stock, preferred stock, warrants to purchase common stock and preferred stock, and debt securities for a total proposed amount of $125,000,000.

S-3/A filing: This S-3/A filing relates to the resale by selling stockholders of up to 600,000 shares of common stock issuable in connection with a Dividend Payment and Exchange Agreement.

S-3/A filing: This S-3/A filing relates to the resale of up to 600,000 shares of common stock by selling stockholders, issuable in connection with a Dividend Payment and Exchange Agreement.

10-Q filing | 97.3M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 600,000 shares of common stock by selling stockholders, issuable in connection with the Dividend Payment and Exchange Agreement.

10-K filing | 74.0M shares outstanding

10-Q filing | 93.7M shares outstanding

S-3 filing: This S-3 filing relates to the resale by selling stockholders of up to 2,100,000 shares of Fortress Biotech, Inc. common stock issuable upon exercise of warrants granted in connection with a senior secured credit agreement.

8-K filing: Fortress Biotech, Inc. entered into a $60.0 million senior secured credit agreement with Oaktree Fund Administration, LLC and granted warrants to purchase up to 1,749,450 shares of common stock at $3.20 per share.

8-K filing: Fortress Biotech, Inc. completed a public offering of 733,332 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $18.00 per share, resulting in net proceeds of approximately $12,143,978 after deducting underwriting discounts and commissions. ($13.2M proceeds)

10-Q filing | 86.1M shares outstanding

8-K filing: Fortress Biotech, Inc. completed a public offering of 638,889 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at $18.00 per share, resulting in net proceeds of approximately $10,580,000. ($11.5M proceeds)

10-Q filing | 82.5M shares outstanding

10-K filing | 78.5M shares outstanding

8-K filing: Fortress Biotech, Inc. entered into an underwriting agreement to sell 625,000 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at $20.00 per share, with an option for the underwriters to purchase an additional 93,750 shares. ($11.5M proceeds)